Cosentyx(Secukinumab) Instructions:Uses,Dosage, Side Effects

1 / 1

Cosentyx(Secukinumab)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Novartis

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

COSENTYX is a recombinant human monoclonal IgG1/κ antibody that selectively binds to interleukin-17A (IL-17A), inhibiting its interaction with the IL-17 receptor. IL-17A is a proinflammatory cytokine implicated in the pathogenesis of several autoimmune and inflammatory disorders. By neutralizing IL-17A, COSENTYX reduces downstream inflammatory signaling, thereby ameliorating disease activity in conditions such as psoriasis, psoriatic arthritis, and axial spondyloarthritis.

COSENTYX is available for subcutaneous or intravenous administration, with dosing regimens tailored to specific indications. Subcutaneous formulations include weight-based dosing for pediatric populations and fixed doses for adults, while intravenous use is reserved for adults with PsA, AS, or nr-axSpA. Common adverse reactions include nasopharyngitis, upper respiratory tract infections, and diarrhea. Critical safety considerations include screening for tuberculosis prior to initiation, monitoring for hypersensitivity reactions, and avoiding live vaccines during therapy. The drug’s efficacy is supported by extensive clinical trials demonstrating significant improvements in disease-specific endpoints, including PASI scores, ACR responses, and ASAS criteria.

Generic name

Cosentyx(Secukinumab)

English name

Secukinumab

Alternative Names

Cosentyx

Drug prices

Indications

COSENTYX is indicated for the treatment of:

1. Plaque Psoriasis (PsO): Moderate to severe in patients aged ≥6 years who are candidates for systemic therapy or phototherapy.

2. Psoriatic Arthritis (PsA): Active, in patients aged ≥2 years.

3. Ankylosing Spondylitis (AS): Active, in adults.

4. Non-radiographic Axial Spondyloarthritis (nr-axSpA): Active, with objective signs of inflammation in adults.

5. Enthesitis-Related Arthritis (ERA): Active, in pediatric patients aged ≥4 years.

6. Hidradenitis Suppurativa (HS): Moderate to severe, in adults.

Therapeutic Target

Interleukin-17A (IL-17A) – COSENTYX is a human monoclonal antibody that selectively binds to IL-17A, a proinflammatory cytokine involved in autoimmune pathophysiology.

Active Ingredients

Secukinumab

Dosage form

INJECTION

specifications

125 mg/5 mL/box

Description

COSENTYX (secukinumab) is a fully human monoclonal antibody that targets IL-17A. It is formulated as a sterile, preservative-free solution for subcutaneous or intravenous administration, used in autoimmune inflammatory conditions. The medication must be administered under appropriate medical supervision.

Dosage and Administration

Vaccination & TB Screening: Complete age-appropriate immunizations and screen for tuberculosis before initiation.

1. Subcutaneous Dosing:

1.1 PsO Adults: 300 mg at Weeks 0, 1, 2, 3, 4, then every 4 weeks (150 mg may be considered).

1.2 PsO Pediatrics (≥6 years):<50 kg: 75 mg;≥50 kg: 150 mg.

1.3 PsA Adults:With PsO: Follow PsO dosing;Without PsO: 150 mg with or without loading dose; may increase to 300 mg if needed.

1.4 PsA Pediatrics (≥2 years):15–<50 kg: 75 mg;≥50 kg: 150 mg.

1.5 AS and nr-axSpA Adults:150 mg with or without loading dose; may increase to 300 mg.

1.6 ERA Pediatrics (≥4 years):15–<50 kg: 75 mg;≥50 kg: 150 mg.

1.7 HS Adults: 300 mg at Weeks 0–4, then every 4 weeks. If inadequate response, increase to every 2 weeks.

2. Intravenous Dosing (AS, PsA, nr-axSpA):

2.1 With loading: 6 mg/kg IV at Week 0, then 1.75 mg/kg every 4 weeks (max 300 mg/infusion).

2.2 Without loading: 1.75 mg/kg every 4 weeks (max 300 mg/infusion).

CATEGORY NAVIGATION